INTRODUCTION
Despite recent approval of some novel drugs, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease and additional treatment options are still needed.
PSMA is a promising target for directing new therapies. It is found in the majority of prostate cancers (1) and its overexpression correlates with traditional adverse prognostic factors (2) . Binding of a ligand leads to internalization via clathrin-coated pits (3) and prolonged retention in the cell.
PSMA-antibody-auristatin conjugates have been considered one option (4) but they face the inherent resistance of mCRPC against most (excepting taxanes) conventional chemotherapies. In contrast, prostate cancer is usually radiosensitive. Radiotherapy is a standard treatment for localized prostate cancer, for palliative management of mCRPC and even radiopharmaceuticals targeting the surrounding bone matrix instead of the tumor itself can improve survival (5) . Therefore it seems more promising that a radioactive PSMA-ligand which is directly internalized into tumor cells will be effective in delivering high doses for systemic endo-radiotherapy. A phase-2 study using the radiolabelled antibody 177 Lu-J591 already demonstrated moderate anti-tumor effects (6) , but the slow diffusion of antibodies into solid lesions and hematotoxicity caused by a long circulation time in blood are limitations (7, 8) . Due to faster kinetics, the PSMA targeted small molecule MIP-1095, when labelled with 131 I demonstrated superior outcomes to the antibody approach with PSA responses in 17/28 patients (9) . Unfortunately, the co-emission of high energy photons from 131 I requires elaborate radiation protection. Unlike 131 I, 177 Lu is a more pure Beta particle emitter and preferable for clinical routine. The DOTAconjugated PSMA-617 can be labelled with 177 Lu-Lu 3+ and was further refined in tumor-targeting with low nanomolar affinity in the range of Ki = 0.37 nM (NAALADase assay) and K i = 2.34 nM (equilibrium dissociation constant on
The precursor PSMA-617 was synthesized as described previously (10) RP-HPLC and ITLC was performed and the final product was diluted in 2 ml 0.9% NaCl.
Pharmacokinetics and Dosimetry
Thorough descriptions of the methods used for evaluation of pharmacokinetics and dosimetry are provided online (Supplemental Methods).
Treatment regime and follow-up
According to German radiation protection laws the patients were treated as in- 
RESULTS

Pharmakokinetics
The initial volume of distribution 1h p. (Table-2 ). The red marrow dose consists from approx. 45% "self-dose", i.e. beta radiation during perfusion and passive diffusion into the interstitial space, and 55% "spill-in" radiation (5% from the delineable source organs, 50% from the "remainder body" including tumor lesions).
Treatment efficacy
8 weeks after the first treatment cycle 21/30 patients demonstrated a decrease in PSA, in 18 patients the decrease was >25%, in 13 patients even >50%.
However, 8 patients demonstrated a rising PSA and 1 patient remained stable ( Fig. 2A) . After 24 weeks, i.e. nearly 6 month after initial therapy, 9/11 patients receiving 3 treatment cycles presented with a sustained decrease in PSA in comparison to the baseline value, the decrease was >25% for all of these 9 patients and >50% in 8 pt (Fig. 2B) . Follow up between the week-8 and week-24 PSA response (Fig. 2C ) revealed that in 8/11 patients the PSA levels by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from further decreased from cycle-1 to cycle-3. One patient who already presented with PSA progression after the 1 st cycle continued therapy due to favorable symptomatic response and had further PSA progression after the 3 rd cycle.
Two patients initially responded to cycle-1 but had PSA relapse by cycle-3; however, in one of them the PSA was still <50% in comparison to baseline. In these patients imaging findings also demonstrated partial remission in comparison to baseline staging.
Imaging based restaging revealed a positive response in 10 of the 11 patients; surprisingly, a positive imaging response was even found in 1 of the 2 patients with rising PSA. 6 patients were re-staged with PSMA-PET/CT and all presented with a decrease of >50% (average of index lesions) in SUVmax (Fig.   3A ). Three patients were assessed with 99m Tc-PSMA-SPECT/CT and presented with visual response (Fig. 3B ). In patients with soft tissue or lymph node metastases (target lesions according to RECIST) response was additionally demonstrated with CT (Fig. 3C) . Also the post-therapeutic emission scans based on the inherent imaging capabilities of 177 Lu (coemission of gamma radiation) seem sufficient to monitor treatment response despite a minimal lower resolution and higher noise (Fig. 4) . Due to the multitude of lesions we did not assess the exact lesion number; as long as the total number of delineable metastases decreased by visual estimation the situation was considered a radiological response. Thus, in similar to the use of bone scans in clinical trials (19), single new lesions were not considered "progressive disease". Clinically, the treatment was able to stabilize the patient's well-being. None of the patients discontinued treatment due to worsening of their general clinical condition. The body weight remained fairly stable (mean body weight at baseline: 83kg, at week-24: 81 kg). None of the 24/30 patients without opioid analgesics at baseline had to start such a medication during follow-up. The dose of the 6/30 patients with opioid analgesics at baseline remained stable.
by
Treatment toxicity
Creatinine and urea as well as liver enzymes were not significantly changed during the complete follow up period, which was 12 weeks for the 19 patients receiving one treatment cycle and 24 weeks for the 11 patients receiving three treatment cycles. Thus, follow-up is sufficient to report acute and mid-term toxicities but not late effects.
Among 15 patients with normal baseline hemoglobin 6 developed I° anemia, 9
patients had no red cell toxicity. In 10 patients with I° anemia before therapy only 3 patients had an decline to II°, 6 patients remained stable and one patient improved to the normal range, this patient simultaneously presented with striking radiological improvement of bone metastases. From 3 patients that already had II° anemia at baseline, one worsened to III° (after only one treatment cycle), one was stable, one improved to I°. In comparison to baseline, 18/27 patients had no worsening of anemia (66%), 9/27 worsened by one grade (33%); no patient had a decline of more than one grade. The only patient with III° anemia had diffuse pattern bone marrow involvement on pretherapeutic imaging. 2 patients had already received substitution of erythrocytes <6 weeks before PSMA-therapy and were omitted from evaluation of anemia.
With regard to white blood cell (WBC) count (Fig. 5A ) 22 patients never developed CTCAE-toxicity higher than baseline. Grade I leucopenia was observed in 6 patients mainly after the third cycle. Grade II was observed in 2 patients, both with diffuse pattern bone marrow involvement.
Platelet count (Fig. 5B ) demonstrated high inter-individual variability. However, in 23 patients the absolute platelet count never dropped below the normal range. In 4 patients grade I thrombocytopenia was observed. One patient by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from developed grade II and one patient grade III thrombocytopenia. Both patients had previously presented with diffuse pattern bone marrow infiltration during imaging and were the same patients who developed the highest WBC toxicity.
In one patient grade IV thrombocytopenia was already present at baseline.
Despite the fact that the absolute platelet count stayed within the normal range (150-300/nl) for 23/30 patients, we observed a relative decline in the mean platelet count of -14% with nadir 4-6 weeks after the first therapy that recovered after 8 weeks. However, in the 11 patients receiving 3 cycles we found a chronic decrease of platelets (-20%) from baseline to week-24.
Most of the patients reported no relevant dysfunction of salivary glands.
Substitution of saliva (spray/gel) was prescribed to 2/30 patients; both developed the xerostomia after the third cycle. After the first and second treatment cycle only temporal xerostomia without relevant loss in quality of life was occasionally reported. Mild fatigue over baseline was regularly reported but only two times it was attributed to affect activities of daily living. Nausea and loss of appetite during the first weeks after therapy were reported infrequently.
DISCUSSION
Here we report our clinical experience with 177 Lu-PSMA-617, which revealed anti-tumor activity in the majority of patients with mild to moderate toxicities.
In contrast to conventional pharmaceuticals, the toxicity and response probability of a radiopharmaceutical predominantly depends on the radiation absorbed dose to healthy and tumor tissue, respectively. There are welldefined radiation tolerance limits for normal organs. Therefore, empiric dose escalation studies can partially be omitted and dosing of radioactive drugs can be based on dosimetry. Our dosimetry data are well in line with two other by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from recent investigations (20,21). The highest normal organ dose was found for the salivary glands. Thus, the sporadic incidence of reversible xerostomia which was mainly observed after the third cycle is reasonable taking into account published radiation tolerance limits (22). However, if mild xerostomia is considered to be an annoying but harmless side effect, kidneys are the only essential dose limiting organs and their tolerance limits would permit about twice the cumulative dose, i.e. 36 GBq 177 Lu-PSMA-617 (23), which vice versa would still stay below the limits to provoke severe and irreversible xerostomia (22). Additionally, recent attempts to reduce kidney uptake of PSMA-ligands raise hope to further increase the therapeutic index (24). Selecting the ideal single fraction dose is more challenging because bone-marrow reserve can be reduced after previous chemotherapy and the published tolerance limits are not reliable (25). Also dosimetry can underestimate red-marrow dose because the beta-radiation arising from bone metastases cannot be sufficiently modeled. The 497 keV beta-energy of 177 Lu corresponds to a mean/max tissue range of only 0.5mm/2mm (i.e. 10-50 cell diameters) and it is plausible to neglect this dose contribution if only a limited number of solid bone metastases are present. However, it might be relevant in case of diffuse bone-marrow involvement. Therefore, we initially administered conservative 4 GBq fractions.
Once it became clear, that only diffuse-type bone-marrow involvement, eventually in combination with previous chemotherapy, present a risk factor for higher hematotoxicity, we escalated to 6 GBq and patients with diffuse-pattern were subsequently stratified to receive PSMA-617 labeled with an alpha emitter. Targeted alpha radiation therapy was already demonstrated to reduce red-marrow toxicity in similar situations (26). However, the reliability of this tailored approach has still to be proven. Despite moderate acute hematotoxicity, we observed a chronic decline of platelets during 3 cycles, thus further dose escalations of 177 Lu-PSMA-617 should be conducted cautiously.
Nevertheless, there is still some room to improve the treatment regime. On the other hand, the reported patients include some selection bias. Patients with diffuse bone-marrow involvement were excluded, once it became apparent that these patients have a higher probability to develop by on October 14, 2017 
